

Ning Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5881262/publications.pdf>

Version: 2024-02-01

21
papers

354
citations

933447

10
h-index

839539

18
g-index

22
all docs

22
docs citations

22
times ranked

497
citing authors

#	ARTICLE	IF	CITATIONS
1	Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e797.	4.0	5
2	Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China. <i>Annals of Surgical Oncology</i> , 2021, 28, 1238-1246.	1.5	11
3	A new risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199766.	1.0	1
4	Molecular Heterogeneity of Xp11.2 Translocation Renal Cell Carcinoma: The Correlation Between Split Signal Pattern in FISH and Prognosis. <i>Cancer Management and Research</i> , 2021, Volume 13, 2419-2431.	1.9	1
5	The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC. <i>International Journal of Biological Macromolecules</i> , 2021, 176, 437-447.	7.5	10
6	Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?. <i>BMC Cancer</i> , 2020, 20, 1182.	2.6	6
7	Comparative Clinicopathologic Characteristics and Outcomes of Paediatric and Adult Xp11 Translocation Renal Cell Carcinomas: a Retrospective Multicentre Study in China. <i>Scientific Reports</i> , 2020, 10, 2249.	3.3	9
8	TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 119.	8.6	32
9	Does the Fuhrman or World Health Organization/International Society of Urological Pathology Grading System Apply to the Xp11.2 Translocation Renal Cell Carcinoma?. <i>American Journal of Pathology</i> , 2018, 188, 929-936.	3.8	9
10	Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients. <i>BMC Urology</i> , 2018, 18, 60.	1.4	12
11	Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 530.e1-530.e6.	1.6	26
12	Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion. <i>Journal of International Medical Research</i> , 2017, 45, 1287-1296.	1.0	9
13	PPAR δ Alleviates Right Ventricular Failure Secondary to Pulmonary Arterial Hypertension in Rats. <i>International Heart Journal</i> , 2017, 58, 948-956.	1.0	10
14	PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue. <i>PLoS ONE</i> , 2017, 12, e0185337.	2.5	11
15	Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease. <i>World Journal of Surgical Oncology</i> , 2016, 14, 193.	1.9	16
16	Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies. <i>BMC Urology</i> , 2016, 16, 40.	1.4	28
17	Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis. <i>PLoS ONE</i> , 2016, 11, e0166897.	2.5	25
18	Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1. <i>Prostate</i> , 2015, 75, 1896-1903.	2.3	68

#	ARTICLE	IF	CITATIONS
19	Newly Designed Break-Apart and ASPL-TFE3 Dual-Fusion FISH Assay Are Useful in Diagnosing Xp11.2 Translocation Renal Cell Carcinoma and ASPL-TFE3 Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e873.	1.0	13
20	Pseudocapsule of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: a clue for tumor enucleation?. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5403-10.	0.5	9
21	Improved outcome of percutaneous radiofrequency ablation in renal cell carcinoma: a retrospective study of intraoperative contrast-enhanced ultrasonography in 73 patients. <i>Abdominal Radiology</i> , 2012, 37, 885-891.	2.1	40